Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.64 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.63 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | CTSK | P43235 | 4/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.57 |
| ▸ | CTSS | P25774 | 2/20 | 0.57 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28595041 | 1.00 | PPARA (0.64) | PPARAFOLH1PPARGCTSKCTSL | |
| SCHEMBL1171673 | 1.00 | PPARA (0.64) | PPARAFOLH1PPARGCTSKCTSL | |
| SCHEMBL5827383 | 0.94 | PPARA (0.62) | PPARAFOLH1PPARGCTSKCTSL | |
| SCHEMBL21837541 | 0.94 | PPARA (0.58) | PPARAFOLH1PPARGCTSKCTSL | |
| SCHEMBL21837546 | 0.94 | PPARA (0.58) | PPARAFOLH1PPARGCTSKCTSL | |
| SCHEMBL7319742 | 0.91 | TACR1 (0.62) | CTSKCTSLCTSSTACR1CTSB | |
| SCHEMBL4391662 | 0.90 | PPARA (0.57) | PPARAFOLH1PPARGCTSKCTSL | |
| SCHEMBL1170973 | 0.89 | CTSK (0.56) | PPARAFOLH1PPARGCTSKCTSL | |
| SCHEMBL31456194 | 0.89 | CTSK (0.60) | PPARAFOLH1CTSKCTSLCTSS | |
| SCHEMBL16351361 | 0.88 | KYNU (0.62) | PPARACTSKCTSLCTSSTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| WO-2025098391-A9 | SELECTIVE DRUG RELEASE FROM CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | NONA BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2026-04-30 | — | — | WO | disclosed |
| EP-3672582-B1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS SINAI MEDICAL CENTER (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260015316-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2026-01-15 | — | — | US | disclosed |
| US-12421185-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2025098391-A1 | SELECTIVE DRUG RELEASE FROM CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | NONA BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2025-05-15 | — | — | WO | disclosed |
| CN-115053184-B | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2024-12-06 | — | — | CN | disclosed |
| CN-118619851-A | Aminooxyacid-based antibacterial compounds and methods thereof | 香港大学 | 2024-09-10 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-4939241-A | Diazo serines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-07-03 | — | — | US | disclosed |
| WO-1990000399-A1 | RETROVIRAL PROTEASE BINDING PEPTIDES | SMITHKLINE BECKMAN CORPORATION (US) | 1990-01-25 | — | — | WO | disclosed |
| EP-0352000-A2 | Retroviral protease binding peptides | SMITHKLINE BEECHAM CORPORATION (US) | 1990-01-24 | — | — | EP | disclosed |
| EP-0285085-A2 | Amino acid derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-10-05 | — | — | EP | disclosed |
| US-4668683-A | Cardiotonic quinazoline derivatives | KYOWA HAKKO KOGYO K.K. (JP) | 1987-05-26 | — | — | US | disclosed |
| EP-0195667-A2 | Cardiotonic quinazoline derivatives | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1986-09-24 | — | — | EP | disclosed |
| US-4564471-A | N-/BENZYLOXYCARBONYL/ASPARTYLPHENYLALANINE | AJINOMOTO CO., INC. (JP) | 1986-01-14 | — | — | US | disclosed |
| EP-0027319-A2 | Method for reductive elimination of protecting groups and preparative process using such method | AJINOMOTO CO., INC. (JP) | 1981-04-22 | — | — | EP | disclosed |
| US-4087520-A | Lowering blood pressure with new L-3-(3,4-dihydroxyphenyl)-2-methyl-alanine peptides | BOEHRINGER MANNHEIM GMBH (DT) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | PPARA 1878/4885FOLH1 4283/4885PPARG 853/4885 |
| US-12421185-B2 | Compositions and methods for treating cancer | TSG101, RNASE1, TP53 | PPARA 2140/4885FOLH1 25/4885PPARG 1746/4885 |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | CETP, SLC43A1, SLC27A1 | PPARA 1752/4885FOLH1 3754/4885PPARG 2783/4885 |
| US-20260015316-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | GLI1, RCC2, BRCA1 | PPARA 3250/4885FOLH1 40/4885PPARG 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.